A few ASX stocks, given below, after falling from higher grounds that they hit earlier are now undergoing base formations. The potential trajectory that these normally follow after consolidation is either partial or full retracement. Investors can add such stocks to their portfolio according to their risk profile.
Mesoblast Limited (ASX: MSB)
has successfully launched its first FDA approved mesenchymal stromal cell therapy Ryoncil. It is for the children with steroid refractory acute graft versus host disease (SR-aGvHD). Ryoncil has generated US$13.2 million in revenue within one quarter since its U.S. launch in March 2025. It now covers over 250 million insured lives including mandatory Medicaid across all states. The therapy benefits from seven years of orphan drug exclusivity and biologic exclusivity until 2036 and is backed by patents lasting through 2044. Mesoblast is expanding Ryoncil’s use in adult trials and progressing its rexlemestrocel-L product for heart failure and chronic low back pain demonstrating a strong commitment to advancing regenerative medicine solutions for severe inflammatory conditions.
has announced its full year results for Financial Year 2025. It reported an 8% increase in Annualised Contract Value to $228.4 million. Revenue remained steady at $221.5 million while Cash EBITDA rose by 24.5% to reach $37.2 million. However, Statutory EBITDA declined by 14.8% to $47.6 million and this was largely due to higher R&D expenses and legal costs. The company maintained a positive cash flow and ended the year with $40 million in cash. Nuix continues focusing on larger contracts and advancing Nuix Neo solutions expecting revenue growth to outpace operating costs in FY26.
Ora Banda Mining Limited (ASX: OBM)
has reported a record Financial Year 2025 results. Revenue surged to $404.3 million marking a 89% increase from FY24. This was driven by higher production and gold prices. EBITDA rose by 243% to reach $184.6 million while net profit after tax soared by 575% to reach $186.1 million. This included a $73.1 million tax benefit from deferred tax assets. The company produced a record 92,399 ounces of gold boosted by stronger output from its Riverina Underground and the new Sand King mine. Riverina Underground repaid its capital in just 18 months and Sand King reached steady production on schedule. Ora Banda plans to continue growth with a focus on underground mining and plans ~$160 million for exploration and development in FY26.
Viva Leisure Limited (ASX: VVA)
has delivered its best financial performance yet in Financial Year 2025. The company has reported a record revenue of $211.3 million marking a 30% increase from the prior year. EBITDA also saw an increase of $99.1 million which was up by 25.6%. The company expanded its membership base to over 621K across 491 locations highlighting strong growth in both corporate and franchise segments. Technology, Payments, Licensing & Services revenue soared 127.7% and was driven by initiatives like Viva Pay and digital solutions. Investments in Boutique Fitness Studios and World Gym Australia fueled franchise network expansion with 170 new franchise locations sold. Viva has reinvested $60.9 million into growth and has maintained a robust cash flow positioning itself for continued expansion. The company enters Financial Year 2026 with confidence focusing on network optimization, technology rollout and operational excellence to sustain growth.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
